SARS-CoV-2 can trigger chronic fatigue syndrome
Charité study provides evidence to support long-held suspicion
Peer-Reviewed PublicationIMAGE: ME/CFS IS CHARACTERIZED BY WEAKNESS AND/OR EXCESSIVE MUSCLE WEAKNESS FOLLOWING ACTIVITY. THIS DEVICE ENABLES RESEARCHERS TO MEASURE GRIP STRENGTH. view more
CREDIT: © CHARITÉ | ANJA HAGEMANN
Since the beginning of the pandemic, SARS-CoV-2 has been suspected of causing chronic fatigue syndrome (ME/CFS). A well-controlled study conducted by a group of researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) has now shown that, even after mild COVID-19, a subset of patients will develop symptoms which meet the diagnostic criteria for ME/CFS. Their findings also describe a second subset of post-COVID patients with similar symptoms. Differences in laboratory results between these groups may indicate differences in underlying mechanisms. The researchers’ findings have been published in Nature Communications*.
“Suspicions that COVID-19 might trigger ME/CFS initially arose as early as during the first wave of the pandemic,” says Prof. Dr. Carmen Scheibenbogen, Acting Director of Charité’s Institute of Medical Immunology on Campus Virchow-Klinikum. Prof. Scheibenbogen also oversees the work of the ‘Charité Fatigue Center’, which specializes in the diagnosis of ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome), a debilitating condition characterized by severe physical fatigue. The Center received its first requests from patients after SARS-CoV-2 infection as early as the summer of 2020. Since then, there has been accumulating evidence of a causal link between COVID-19 and ME/CFS, a disease which often causes severe physical impairments.
“Providing the scientific evidence to confirm these assumptions, however, is anything but a trivial task,” explains Prof. Scheibenbogen. She continues: “This is partly due to the paucity of research into ME/CFS and the fact that there are no universally accepted diagnostic criteria. Thanks to an extremely thorough diagnostic process and a comprehensive comparison with patients who developed ME/CFS following non-COVID-related infections, we have now been able to show that COVID-19 can trigger ME/CFS.”
As part of this study, experts from Charité’s Post-COVID Network examined 42 individuals who presented at the Center with persistent, severe fatigue and impaired day-to-day functioning six months after their SARS-CoV-2 infection. Most of the study participants were unable to perform light work for more than two to four hours a day; some were unable to work and struggled to look after themselves. Only three out of the 42 patients examined needed hospital care during their initial (acute) SARS-CoV-2 infection, but none required oxygen. 32 of the patients met the WHO classification of mild COVID-19, meaning they did not develop pneumonia, but had fairly severe symptoms including fever, cough, muscle pain and joint pain for between one and two weeks. As all of the participants’ infections occurred during the first wave of the pandemic, none of them had been vaccinated. At Charité, all of the individuals concerned were examined by an interdisciplinary team of neurologists, immunologists, rheumatologists, cardiologists, endocrinologists and pulmonologists with many years’ experience in the diagnosis of ME/CFS. For comparison, the researchers then examined 19 age- and gender-matched individuals who had developed ME/CFS following a similar period of illness due to a non-COVID-related infection.
The researchers used the ‘Canadian Consensus Criteria’ to establish a diagnosis of ME/CFS. “In addition to having been scientifically developed, this catalog of criteria has been proven as a reliable diagnostic tool for chronic fatigue syndrome in clinical practice,” explains the study’s other co-lead, Dr. Judith Bellmann-Strobl, who heads the multidisciplinary outpatient department at the Experimental and Clinical Research Center (ECRC), a facility jointly operated by Charité and the MDC. According to the Canadian Consensus Criteria, approximately half of the post-COVID patients examined met the diagnostic criteria for ME/CFS. While the other half presented with similar symptoms, their post-exertional malaise was milder and only lasted for a few hours. In contrast, ME/CFS patients reported post-exertional malaise which persisted into the following day. Summarizing the researchers’ findings, Dr. Bellman-Strobl says: “We can therefore distinguish between two groups of post-COVID patients with severely impaired physical functioning.”
In addition to collating data on symptoms, the researchers also determined various laboratory parameters. They then compared these with hand grip strength, which was reduced in the majority of the participants examined. “We furthermore found that individuals with milder exertional intolerance had reduced hand grip strength if they had elevated levels of the cytokine interleukin 8. In these cases, reduced muscular strength may be caused by a persistent inflammatory response,” says Prof. Scheibenbogen. “In the ME/CFS group, however, hand grip strength was correlated with the hormone NT-proBNP, which can be released by muscle cells when oxygen supply is insufficient. This suggests that, in these individuals, muscle weakness may be caused by an impaired blood supply.” According to the researchers’ preliminary observations, the two groups may also be distinguishable in terms of disease progression. “In many people whose symptoms are indicative of ME/CFS but who do not meet diagnostic criteria, symptoms appear to improve over time,” explains Prof. Scheibenbogen.
These new findings may help researchers to develop specific treatments for post-COVID syndrome (‘Long Covid’) and ME/CFS. “Our data also provide further evidence that ME/CFS is not a psychosomatic disorder but a severe physical disease which can be measured and diagnosed using objective methods,” emphasizes Prof. Scheibenbogen. “Unfortunately, current treatments for ME/CFS are purely symptomatic in nature. I would therefore urge even young people to protect themselves against SARS-CoV-2 by getting vaccinated and wearing an FFP2 mask.”
*Kedor C et al. Post COVID-19 Chronic Fatigue Syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity results from a prospective observational study. Nat Comm 2022 Aug 30. doi: 10.1038/s41467-022-32507-6
About ME/CFS
ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) is a severe disease which is usually triggered by an infection and often develops into a chronic condition. The hallmark of the condition is post-exertional malaise: a severe exacerbation in the severity of symptoms following even mild physical or mental exertion. Post-exertional malaise can occur immediately after exertion or after a delay of hours or the following day and will last at least until the next day, but may persist for longer. In addition to fatigue and physical weakness, it is also frequently associated with headache or muscle pain, as well as neurocognitive, immunological symptoms and symptoms of autonomic nervous system dysfunction. Before the pandemic, prevalence estimates for ME/CFS in the general public were approximately 0.3 percent. Experts assume that the COVID-19 pandemic will result in a significant increase in the number of people affected by ME/CFS. Until now, viruses known to trigger ME/CFS have included the Epstein-Barr virus, the Dengue virus and enteroviruses, among others. Cases of ME/CFS have also been reported in individuals infected with the first SARS coronavirus during 2002/2003. ME/CFS should be distinguished from post-infectious fatigue, which is associated with a large number of infectious diseases and can persist for weeks and even months.
Treatment of ME/CFS at Charité
Charité currently operates a total of eleven special outpatient clinics which are dedicated to the diagnosis and treatment of people with persistent symptoms following SARS-CoV-2 infection. Spread across different departments and institutes, these clinics form part of the Post-COVID Network, which enables them to work closely together in addition to providing a range of treatments based on the patients’ cardinal symptoms. The Network also comprises the Charité Fatigue Center, the key point of contact for individuals who experience persistent severe fatigue, difficulty concentrating and exertional intolerance six months or more after contracting COVID-19. Patients with ME/CFS also have access to an interdisciplinary care which is offered as part of the CFS_CARE project and includes a specially developed rehabilitation program.
About this study
The data underpinning the published article were generated using the Pa-COVID-19 platform. Pa-COVID-19 is a prospective patient registry for patients with COVID-19 at Charité. The aim of the registry is to collate comprehensive clinical and molecular data on patients with COVID-19 in order to identify individual risk factors for severe disease, as well as prognostic biomarkers and treatment targets. The protocol for the study is available here.
JOURNAL
Nature Communications
ARTICLE TITLE
A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
